Philippe Berthon Email and Phone Number
Philippe Berthon work email
- Valid
Philippe Berthon personal email
Philippe Berthon phone numbers
Experienced entrepreneur / CEO in the biotechnology industry, current CEO of Blue Bees Therapeutics, a biotech company developing immunotherapeutics to fight cancers, as well as a partner at DNA Finance, experts in investments and value creation in the healthcare industry. Dr Berthon is the former CEO of Culture Top (sold to Eurofins), Tridek One, Aurgalys (founder, sold to Genesta/ In Extenso), Vaxon-Biotech, Urogene (co-founder, sold to Pierre Fabre Group) and CeRePP (co-founder). Dr Philippe Berthon has demonstrated significant experience in strategic planning, financing, operations, business development, and R&D with more than 50 scientific & international publications. Due to his life experience, Dr Berthon is recognized as a specialist in Life Sciences and Healthcare.From 2014 to 2020, Dr Berthon also served as Mayor of Soisy-sur-Ecole, a small town in the south of Essonne - Ile de France and Vice-President of the Communauté de Communes des Deux Vallées in charge of business development.
-
Chief Executive OfficerBlue Bees Therapeutics Feb 2022 - PresentBlue Bees Therapeutics is a biotech company funded early 2022, which aims to develop new immunotherapies against cancer based on a breakthrough technology, to generate a series of proteins / MAbs potentiating the anti-tumor immune response. We are currently validating a first drug candidate whose development is supported by SATT Paris-Saclay. Blue Bees Therapeutics is a CEA Spin-off from the Paris-Saclay Joliot Curie Institute.
-
PartnerDna Finance Mar 2019 - PresentParis, Île-De-France, FrDNA finance team is experts in investments and value creation in the healthcare industry. We leverage our Bioteh Promise investment fund expertise and capabilities to create value through our deep understanding of the biotech and medtech ecosystem. DNA Finance offers strategic consulting and value generation advisory to healthcare companies, including fund raising. -
Chief Executive OfficerCulture Top Mar 2020 - Mar 2022Culture Top is an in vitro diagnostics (IVD) company in infectious disease, co-founded in 2015 by Eurobio Scientific [Euronext: ALERS.PA] and the IHU Méditerranée Infection (Marseille). During our mandate as CEO, we have finalized a private financing of 3M€, secured the sale of the company to Eurofins [Euronext: ERF.PA], managed Eurobio Scientific exit, and initiated an industrial and commercial partnership. The objectives are to bring to the market a full range of products to improve infection detection.
-
Vice-President, Business Development, Communauté De Communes Des Deux Vallées (Cc2V)Communauté De Communes Des Deux Vallées (Cc2V) Mar 2014 - Jul 2020The CC2V is a local authority regrouping 15 municipalities, including Soisy-sur-Ecole. As elected VP, we were in charge of business development. Our main responsibility was the commercialization of an industrial and commercial park of 35 ha, with 75 companies and 500 jobs created or installed during our mandate
-
Mayor Of Soisy-Sur-EcoleCity Of Soisy-Sur-Ecole Mar 2014 - May 2020Soisy-sur-Ecole is a small town located south of Essonne, Ile-de-France. As mayor, we oversee all departments, including finance, education, town planning and housing, roads and transportation, development and security, with the support of a 15-person city council and the city staff. Philippe Berthon has been a member of the city council since 2008, until 2020, and resigned in May 2020.
-
Chief Executive OfficerTridek One Mar 2019 - Mar 2020Paris, Île-De-France, FrTridek-One is a biotechnology company developing a novel CD31 agonist approach to modulate immune activation and so provide a new way to manage inflammatory conditions. We have raised 3M€ in mid-2019, supported by two venture funds, AdBio Partners (Fr) and Advent Life Sciences (UK). -
Chairman & Chief Executive Officer, FounderAurgalys Sas Feb 2008 - Jul 2019Aurgalys, was a corporate advisory firm specialized in life sciences and healthcare. Aurgalys has been acquired by Genesta Finance in june 2018 to create a group able to cover all technology sectors. Former Aurgalys team members brought their life sciences and healthcare expertise in the new entity.Aurgalys proposed a full range of services that suits fast growing/ life science & healthcare companies and investor needs: Corporate Finance & Fund Raising, IPO (CIF & Listing Sponsor Euronext), Independant Valuation, Equity Research (SFAF registered), Investor relations, Interim Management, Company / Investor Assistance and consulting, Due Diligence, Business Development.Some disclosed customers: BioAlliance/ Onxeo, DNA Therapeutics, Global BioEnergies, Diaxonhit/ Eurobio Scientific, Génopole, Cellectis, Evolva, MyoPowers, Sensorion, Abivax, Ose Immuno, BioCorp, Noxxon Pharma, Intrasense, Implanet, Medial Lab, Parx Plastics, ...
-
Board Member, Chairman Corporate Finance CommitteeFrance Biotech May 2006 - Jun 2011Paris, Île-De-France, FrFrench Association for Biotechnology: France Biotech mission is to contribute to position France and Europe as leaders in the healthtech industry.Philippe set up the France Biotech - Corporate Finance Committee and chaired it until 2011. -
Chairman & Chief Executive OfficerVaxon Biotech Feb 2004 - Jan 2008BioPharmaceutical company which develops immuno-therapeutics to treat cancer. Most advanced compounds Vx-001 was currently in phase IIb/III in lung cancer (NSCLC). Philippe managed the company restructuring, private equity financing for 7M€, and launch of VX-001 clinical trials.
-
Founder & Chief Executive Officer, Chief Scientific OfficerUrogene Mar 1998 - Dec 2004Founded UroGene in March 1998, as a spin-off of my University Paris VII lab (Upres 3104/ CeRePP). Biotechnology/BioPharmaceutical company dedicated to urological cancer. We raised >25M€ and developed a preclinical and clinical portfolio up to phase II. Urogene was sold to group Pierre Fabre early 2005.
-
Director, Co-FounderUrology Research Lab - Cerepp - Paris Vii University U3104 Mar 1995 - Nov 1999University of Paris VII (Denis Diderot) and St Louis Hospital research lab dedicated to prostate cancer research.
-
Senior Post-Doctoral FellowCancer Research Unit - University Of York, Uk 1991 - 1995University research lab dedicated to prostate cancer research
Philippe Berthon Skills
Philippe Berthon Education Details
-
Pierre And Marie Curie UniversityOncology -
Hec ParisBusiness Management
Frequently Asked Questions about Philippe Berthon
What company does Philippe Berthon work for?
Philippe Berthon works for Blue Bees Therapeutics
What is Philippe Berthon's role at the current company?
Philippe Berthon's current role is Chief Executive Officer, Blue Bees Therapeutics - Partner, DNA Finance.
What is Philippe Berthon's email address?
Philippe Berthon's email address is ph****@****lys.com
What is Philippe Berthon's direct phone number?
Philippe Berthon's direct phone number is +339630*****
What schools did Philippe Berthon attend?
Philippe Berthon attended Pierre And Marie Curie University, Hec Paris.
What skills is Philippe Berthon known for?
Philippe Berthon has skills like Due Diligence, Mergers, Corporate Development, Biotechnology, Technology Transfer, Lifesciences, Clinical Development, Start Ups, Pharmaceutical Industry, Drug Discovery, Medical Devices, Venture Capital.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial